<?xml version="1.0" encoding="UTF-8"?>
<ref id="B103">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jasenosky</surname>
    <given-names>L. D.</given-names>
   </name>
   <name>
    <surname>Cadena</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Mire</surname>
    <given-names>C. E.</given-names>
   </name>
   <name>
    <surname>Borisevich</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Haridas</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Ranjbar</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2019</year>). 
  <article-title>The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits ebola virus.</article-title>
  <source>
   <italic>iScience</italic>
  </source>
  <volume>19</volume>
  <fpage>1279</fpage>â€“
  <lpage>1290</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.isci.2019.07.003</pub-id>
  <?supplied-pmid 31402258?>
  <pub-id pub-id-type="pmid">31402258</pub-id>
 </mixed-citation>
</ref>
